Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 20/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 20/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 20/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 20/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 20/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 20/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097864 | 0.91 | HDAC3 (0.84) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10097856 | 0.85 | HDAC3 (0.74) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8239418 | 0.84 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10097910 | 0.83 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10097879 | 0.83 | HDAC3 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10097912 | 0.82 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12328099 | 0.82 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12328097 | 0.81 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12295595 | 0.81 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12295599 | 0.81 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-9078896-B2 | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2015-07-14 | — | — | US | disclosed |
| US-20140135341-A1 | Pyridine And Pyrimidine Derivatives As Inhibitors Of Histone Deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-05-15 | — | — | US | disclosed |
| US-8664223-B2 | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V (BE) | 2014-03-04 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20130143898-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-06-06 | — | — | US | disclosed |
| EP-1979326-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-03 | — | — | EP | disclosed |
| US-8114876-B2 | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-8114876-B2 | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-20090143401-A1 | Pyridine and Pyrimidine Derivatives as Inhibitors of Histone Deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143401-A1 | Pyridine and Pyrimidine Derivatives as Inhibitors of Histone Deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC3 1/4885HDAC4 7/4885HDAC1 2/4885 |
| US-20140135341-A1 | Pyridine And Pyrimidine Derivatives As Inhibitors Of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | HDAC3 3/4885HDAC4 8/4885HDAC1 1/4885 |
| US-20090143401-A1 | Pyridine and Pyrimidine Derivatives as Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | HDAC3 3/4885HDAC4 8/4885HDAC1 1/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC3 1/4885HDAC4 7/4885HDAC1 2/4885 |
| US-20130143898-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | HDAC3 3/4885HDAC4 8/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.